Using prognosis to guide early detection and treatment selection in non‐metastatic prostate cancer

Gnanapragasam, Vincent; Barrett, Tristan; Massie, Charlie E.; Pacey, Simon; Warren, Anne Y.

doi:10.1111/bju.14637

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa) is the most frequently diagnosed cancer in men worldwide, with an increasing incidence observed over the past decade ( 1 , 2 ). Most PCa patient present with indolent and slowly progressing tumor, while those with high-grade PCa tends to have bone metastasis, which in turn leads to disastrous complications and high mortality rates ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundProstate cancer (PCa) is one of the most common tumors and the second leading cause of cancer-related death in men. The discovery of novel biomarkers for PCa diagnosis in the early stage, as well as discriminating aggressive PCa from non-aggressive PCa continue to pose a challenge. The aim of this study was to identify serum proteins that were sensitive and specific enough to detect early-stage and aggressive PCa.MethodsThe serum proteomic profiling of patients with PCa and benign prostatic hyperplasia (BPH) was comprehensively analyzed using data-independent acquisition mass spectrometry (DIA-MS), and the bioinformatics analysis was performed. The differentially expressed proteins (DEPs) of interest were further verified by enzyme-linked immunosorbent assay (ELISA) and immunoturbidimetry assay.ResultsStatistically significant difference in abundance showed 56 DEPs between early-stage PCa and BPH and 47 DEPs between aggressive and non-aggressive PCa patients. In addition, the verification results showed that serum L-selectin concentration was significantly higher (p<0.05) in Gleason 6 PCa when compared with BPH, and the concentration of osteopontin (SPP1) and ceruloplasmin (CP) increased with higher Gleason score.ConclusionsDIA-MS has great potential in cancer-related biomarker screening. Our data demonstrated that adding SPP1 and CP to PSA improved the separation of Gleason 7 (4 + 3) or above from Gleason 7 (3 + 4) or below compared with PSA diagnosis alone. Serum SPP1 and CP could be effective biomarkers to differentiate aggressive PCa (especially Gleason 7 (4 + 3) or above) from non-aggressive disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

The Quest for the Optimal Prostate Biopsy Regime for the 21st Century

Gnanapragasam

Barrett

2019

European Urology

View full text Add to dashboard Cite

The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload

Sushentsev

Caglič

Sala

et al. 2020

The British Journal of Radiology

View full text Add to dashboard Cite

Objective: To introduce capped biparametric (bp) MRI slots for follow-up imaging of prostate cancer patients enrolled in active surveillance (AS) and evaluate the effect on weekly variation in the number of AS cases and total MRI workload. Methods: Three 20 min bpMRI AS slots on two separate days were introduced at Addenbrooke’s Hospital, Cambridge. The weekly numbers of total prostate MRIs and AS cases recorded 15 months before and after the change (Groups 1 and 2, respectively). An intergroup variation in the weekly scan numbers was assessed using the coefficient of variance (CV) and mean absolute deviation; the Mann–Whitney U test was used for an intergroup comparison of the latter. Results: In AS patients, a shift from considerable to moderate variation in weekly scan numbers was observed between the two groups (CV, 51.7 and 26.8%, respectively); mean absolute deviation of AS scans also demonstrated a significant decrease in Group 2 (1.28 vs 2.58 in Group 1; p < 0.001). No significant changes in the variation in total prostate MRIs were observed, despite a 10% increased workload in Group 2. Conclusion: A significant reduction in weekly variation of AS cases was demonstrated following the introduction of capped bpMRI slots, which can be used for more accurate long-term planning of MRI workload. Advances in knowledge: The paper illustrates the potential of introducing capped AS MRI slots using a bp protocol to reduce weekly variation in demand and allow for optimising workflow, which will be increasingly important as the demands on radiology departments increase worldwide.

show abstract

Using prognosis to guide early detection and treatment selection in non‐metastatic prostate cancer

Cited by 3 publications

References 6 publications

Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer

Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer

The Quest for the Optimal Prostate Biopsy Regime for the 21st Century

The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload

Contact Info

Product

Resources

About